Targeting MAPK in recurrent, low-grade serous ovarian cancer
- PMID: 35123677
- DOI: 10.1016/S0140-6736(21)02338-2
Targeting MAPK in recurrent, low-grade serous ovarian cancer
Conflict of interest statement
SPB reports grants and institutional support for clinical trials from NuCana, Sierra Oncology, Redx Pharma, UCB Pharma, Astex Pharma, Tesaro, and BerGenBio, all unrelated to the area of work commented on here.
Comment on
-
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.Lancet. 2022 Feb 5;399(10324):541-553. doi: 10.1016/S0140-6736(21)02175-9. Lancet. 2022. PMID: 35123694 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical